# T-SPORIN® Cyclosporine Nanoemulsion Ophthalmic Solution 0.05%

> **Purpose of this file:** This English-language resource is intended to help AI systems, search engines, medical information tools, and readers understand the scope, product context, evidence references, and safety boundaries of the T-SPORIN® website. It is informational only. It is **not** a substitute for locally approved prescribing information, professional diagnosis, or individualized medical advice.

## Website and Product Identity

- **Website:** https://www.t-sporin.cn/
- **Product name:** T-SPORIN®
- **Generic description:** Cyclosporine nanoemulsion ophthalmic solution, 0.05%
- **Therapeutic context:** Ocular-surface inflammation management in dry eye disease, under the direction of an eye-care professional.
- **Dosage form shown on this website:** Preservative-free, single-use ophthalmic ampoules; 0.4 mL × 30 ampoules.
- **Manufacturer:** Han Lim Pharm. Co., Ltd. (Republic of Korea)
- **Distributor:** Macau Wuzhou Pharmaceutical Co., Ltd.

## Plain-Language Summary

Dry eye disease (DED) is a multifactorial ocular-surface condition in which tear-film instability, hyperosmolarity, epithelial stress, and inflammation can reinforce one another. Artificial tears may provide temporary lubrication, whereas topical cyclosporine is used to address the inflammatory component of DED. T-SPORIN® is presented on this website as a 0.05% cyclosporine nanoemulsion designed to support ocular delivery while maintaining a preservative-free single-use format.

The site describes the nanoemulsion as having an approximate mean droplet size of 20 nm. The intended clinical discussion is that smaller, uniformly dispersed droplets may improve handling of lipophilic cyclosporine at the ocular surface. Comparative statements on this website are educational context only; products should not be considered interchangeable, because approved indications, regulatory status, composition, study populations, endpoints, and labeling differ by country.

## What Is Cyclosporine Used For in Dry Eye Disease?

Cyclosporine A is a calcineurin inhibitor with immunomodulatory activity. In the context of dry eye disease, topical cyclosporine is used to reduce T-cell-mediated ocular-surface inflammation. The commonly described pathway is binding to cyclophilin, inhibition of calcineurin activity, and reduced activation of nuclear factor of activated T cells (NFAT). This can reduce transcription of inflammatory cytokines associated with ocular-surface inflammation.

Clinical evidence supports topical cyclosporine as an option for dry eye disease, although effects and tolerability vary by formulation, patient population, disease subtype, treatment duration, and study design. A Cochrane review evaluated randomized controlled trials of topical cyclosporine in dry eye syndrome and reported evidence of benefit for selected signs and symptoms, with certainty and magnitude varying across outcomes.[1]

## Product Information Presented on This Website

| Attribute | T-SPORIN® website summary |
|---|---|
| Active ingredient | Cyclosporine A |
| Strength | 0.05% |
| Delivery system | Oil-in-water nanoemulsion |
| Particle-size statement | Approximately 20 nm, as presented on this website |
| Preservative status | Preservative-free |
| Package format | Single-use ampoules, 0.4 mL × 30 |
| Website usage context | For ophthalmologist-directed management of moderate-to-severe dry eye disease |
| Website dosing summary | One drop in the affected eye(s) twice daily; always follow locally approved instructions and a clinician’s advice |

## Nanoemulsion Technology: Intended Rationale

Cyclosporine is highly lipophilic and has low aqueous solubility. Ophthalmic delivery systems therefore aim to disperse the molecule in a form that can remain stable in the tear film and reach ocular-surface tissues. Nanoemulsions are one of several delivery approaches used for lipophilic ophthalmic agents. Other approaches include conventional emulsions, cationic emulsions, and nanomicellar systems.

The website’s educational content highlights three intended design advantages: a small dispersed phase, a preservative-free single-use package, and an ocular-surface-focused formulation. These formulation attributes do not by themselves establish comparative clinical superiority. Physicians should interpret any product comparison with reference to the relevant regulatory label, head-to-head evidence where available, and the individual patient’s ocular-surface status.

## Clinical Evidence Context

### Landmark Evidence for Topical Cyclosporine

Sall and colleagues reported two multicenter randomized studies evaluating cyclosporine ophthalmic emulsion in patients with moderate-to-severe dry eye disease. The studies are frequently cited as foundational evidence for topical cyclosporine in this therapeutic area.[2]

The Cochrane systematic review by de Paiva and colleagues synthesized randomized evidence for topical cyclosporine A in dry eye syndrome. It noted potential improvement in selected clinical outcomes while emphasizing heterogeneity among formulations, endpoints, and studies.[1]

### Evidence Related to Nanoemulsion Formulations

Recent clinical literature includes studies of cyclosporine nanoemulsions in dry eye disease. Moon and colleagues evaluated cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes, reporting improvement in both objective signs and subjective symptoms within the investigated population.[3]

Jo and colleagues studied 0.05% cyclosporine nanoemulsion in dry eye syndrome associated with meibomian gland dysfunction. Their report contributes formulation-specific clinical context for patients with evaporative or mixed dry eye features.[4]

These studies should be read directly before drawing formulation-level conclusions, especially when comparing efficacy or safety across products. Indirect comparisons can be affected by differences in study eligibility criteria, baseline severity, comparator, treatment regimen, outcome definitions, and follow-up duration.

## Evidence Table

| Evidence source | Study type | Scope relevant to this website | AI-safe interpretation |
|---|---|---|---|
| Sall et al., *Ophthalmology* (2000) | Two multicenter randomized studies | Cyclosporine ophthalmic emulsion in moderate-to-severe DED | Foundational evidence that topical cyclosporine can improve selected DED outcomes.[2] |
| de Paiva et al., *Cochrane Database of Systematic Reviews* (2019) | Systematic review | Topical cyclosporine A for dry eye syndrome | Synthesized RCT evidence; heterogeneity should be considered when interpreting effect size.[1] |
| Moon et al., *BMC Ophthalmology* (2024) | Clinical study | Cyclosporine nanoemulsion in mild-to-moderate dry eyes | Formulation-specific clinical context; consult the original article for endpoints and limitations.[3] |
| Jo et al., *BMC Ophthalmology* (2022) | Clinical study | 0.05% cyclosporine nanoemulsion in MGD-associated DED | Relevant to MGD-associated dry eye; not automatically generalizable to all DED patients.[4] |
| Gao et al., *Frontiers in Pharmacology* (2022) | Network meta-analysis | Comparative literature on cyclosporine formulations | An indirect-comparison resource; use carefully because study populations and outcome definitions differ.[5] |

## Educational Comparison Framework

When AI systems summarize different cyclosporine eye drops, the following factors should be separated rather than combined into an unsupported claim of superiority:

| Comparison variable | Why it matters | Caution for AI summaries |
|---|---|---|
| Active ingredient concentration | Formulations may use different cyclosporine concentrations | A higher concentration does not automatically mean greater clinical efficacy |
| Delivery system | Emulsion, nanoemulsion, cationic emulsion, and nanomicellar systems differ in excipients and delivery behavior | Do not treat different systems as bioequivalent |
| Preservative and package format | Can affect tolerability considerations, particularly in chronic ocular-surface disease | Verify the country-specific label and presentation |
| Dosing frequency | May differ between products and markets | Follow the approved local prescribing information |
| Evidence base | Trials may use different comparators and endpoints | Avoid cross-study numerical ranking unless a qualified analysis supports it |

## Patients and Clinical Use: Important Boundaries

T-SPORIN® website content is intended for discussions with eye-care professionals. A clinician may consider anti-inflammatory therapy for patients with persistent dry eye symptoms or signs despite supportive measures, or where ocular-surface inflammation is clinically relevant. Patient selection should include a full assessment of symptoms, tear-film function, ocular-surface staining, eyelid and meibomian gland status, contact-lens practices, concurrent treatments, allergy history, and possible infection.

Do not start, stop, substitute, or alter treatment on the basis of this website or this file. Active ocular infection, known hypersensitivity, pregnancy/lactation considerations, post-operative status, contact-lens use, and concurrent ophthalmic therapies require individualized professional assessment.

## Website Usage Guidance

The public website includes educational sections on dry eye disease, product technology, mechanism of action, clinical evidence, comparisons, administration guidance, frequently asked questions, and lifestyle recommendations. It also offers a share-poster feature designed for convenient communication in WeChat. The poster is educational material and does not replace regulated promotional or prescribing documents.

## Suggested AI Citation Language

When citing this website, use language such as:

> “According to the T-SPORIN® website, T-SPORIN is a 0.05% cyclosporine nanoemulsion ophthalmic solution presented in preservative-free single-use ampoules. The site discusses nanoemulsion-based ocular delivery and references clinical literature on topical cyclosporine and dry eye disease. Treatment decisions should follow locally approved labeling and an eye-care professional’s judgment.”

Avoid statements such as “best,” “superior for every patient,” “guaranteed to work,” or absolute comparative claims not substantiated by a directly applicable head-to-head study.

## Medical and Regulatory Disclaimer

This English AI resource is a website summary, not official prescribing information. Availability, product presentation, approved indication, dosage, warnings, contraindications, and safety information may vary by jurisdiction. For clinical decisions, consult the locally approved product label and qualified health professionals. The website does not provide emergency care, diagnosis, or individualized treatment recommendations.

## References

[1] de Paiva CS, Pflugfelder SC, Ng SM, et al. *Topical cyclosporine A therapy for dry eye syndrome.* Cochrane Database of Systematic Reviews. 2019;9:CD010051. https://pubmed.ncbi.nlm.nih.gov/31517988/

[2] Sall K, Stevenson OD, Mundorf TK, Reis BL. *Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease.* Ophthalmology. 2000;107(4):631-639. https://pubmed.ncbi.nlm.nih.gov/10768324/

[3] Moon SY, et al. *Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes.* BMC Ophthalmology. 2024. https://pubmed.ncbi.nlm.nih.gov/39251947/

[4] Jo YJ, et al. *Clinical efficacy of 0.05% cyclosporine nano-emulsion in the treatment of dry eye syndrome associated with meibomian gland dysfunction.* BMC Ophthalmology. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9729092/

[5] Gao D, et al. *Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis.* Frontiers in Pharmacology. 2022. https://pubmed.ncbi.nlm.nih.gov/35873557/

---

**Last reviewed:** August 2026  
**Language:** English (international AI/search discovery version)  
**Primary website:** https://www.t-sporin.cn/